Your browser doesn't support javascript.
COVID-19 in patients with chronic lymphocytic leukemia: a Moscow observational study.
Kochneva, Оlga L; Kislova, Maria; Zhelnova, Evgenya I; Petrenko, Andrei A; Baryakh, Elena A; Yatskov, Konstantin V; Dmitrieva, Elena A; Misurina, Elena N; Nikitin, Konstantin E; Vasilieva, Elena J; Samsonova, Inna V; Ptushkin, Vadim V; Baranova, Ancha; Nikitin, Eugene A.
  • Kochneva ОL; City Clinical Hospital No. 52, Moscow, Russia.
  • Kislova M; Botkin Hospital, Moscow, Russia.
  • Zhelnova EI; City Clinical Hospital No. 52, Moscow, Russia.
  • Petrenko AA; Federal State Budgetary Educational Institution of Further Professional Education "Russian Medical Academy of Continuous Professional Education" of the Ministry of Healthcare of the Russian Federation.
  • Baryakh EA; Department of Radio Engineering and Cybernetics, Moscow Institute of Physics and Technology, Moscow, Russia.
  • Yatskov KV; City Clinical Hospital No. 52, Moscow, Russia.
  • Dmitrieva EA; Federal State Budgetary Educational Institution of Further Professional Education "Russian Medical Academy of Continuous Professional Education" of the Ministry of Healthcare of the Russian Federation.
  • Misurina EN; City Clinical Hospital No. 52, Moscow, Russia.
  • Nikitin KE; Botkin Hospital, Moscow, Russia.
  • Vasilieva EJ; Federal State Budgetary Educational Institution of Further Professional Education "Russian Medical Academy of Continuous Professional Education" of the Ministry of Healthcare of the Russian Federation.
  • Samsonova IV; City Clinical Hospital No. 52, Moscow, Russia.
  • Ptushkin VV; Department of Radio Engineering and Cybernetics, Moscow Institute of Physics and Technology, Moscow, Russia.
  • Baranova A; Davidovsky City Clinical Hospital, Moscow, Russia.
  • Nikitin EA; City Clinical Hospital No. 52, Moscow, Russia.
Leuk Lymphoma ; 63(7): 1607-1616, 2022 07.
Article in English | MEDLINE | ID: covidwho-1684340
ABSTRACT
We describe a retrospective cohort, 156 patients with chronic lymphocytic leukemia (CLL) diagnosed with COVID-19, analyze factors associated with a severe disease course and the effects of various treatment regimens. Anti-SARS-CoV-2 IgG and IgM levels are significantly lower. Patients with CLL are more likely to have a severe course of COVID-19, with IL-6 levels acting as a consistent biomarker of disease severity. Ten patients had recurrent episodes, fatality rate of 20%. Overall survival did not differ between patients receiving ibrutinib monotherapy and anti-CD20 antibodies ± chemotherapy. It seems that the immunodeficiency inherent to CLL influences outcomes to a larger degree than does the treatment. Glucocorticoids are not associated with significant OS improvement whereas anti-cytokine compounds usage seemed to be beneficial in patients with mild pulmonary involvement. Our data attest to the necessity of reorganizing health care for patients with CLL. Early administration of effective antiviral compounds and tailored vaccination protocols are warranted.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Leukemia, Lymphocytic, Chronic, B-Cell / COVID-19 Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Topics: Vaccines Limits: Humans Country/Region as subject: Europa Language: English Journal: Leuk Lymphoma Journal subject: Hematology / Neoplasms Year: 2022 Document Type: Article Affiliation country: 10428194.2022.2034157

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Leukemia, Lymphocytic, Chronic, B-Cell / COVID-19 Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Topics: Vaccines Limits: Humans Country/Region as subject: Europa Language: English Journal: Leuk Lymphoma Journal subject: Hematology / Neoplasms Year: 2022 Document Type: Article Affiliation country: 10428194.2022.2034157